SysGene Biologics

Developing biologics faster, powered by patented platform technologies & deep bioprocess expertise

Founded in 2026, SysGene Biologics is guided by a simple belief: essential biologics should be more accessible and affordable. We bring together biologics expertise, enabling manufacturing technologies and focused bioprocess solutions to help manufacturers address production challenges, improve efficiency and reduce costs while maintaining quality.

From molecule to transferable process
Molecule assessmentStructure, function and quality requirements
Platform selectionBacterial secretion or mammalian expression
Development & analyticsUpstream, downstream, characterization
Scale-up & transfer5 L mammalian; 30–1,000 L microbial; 5,000 L planned

Molecule first

The molecule determines the route, not a one-size-fits-all process.

Every program begins with the molecule’s structure, function and quality requirements, ensuring that the most appropriate platform and development strategy are selected.

Two platform routes

Platform selection follows the molecule

Bacterial secretion

Patented Bacterial Secretion Platform

Designed to produce suitable recombinant proteins and peptides directly into the culture medium. For compatible molecules, extracellular secretion can simplify recovery by reducing reliance on cell lysis, inclusion-body isolation, solubilization and refolding.

    Evaluate a Molecule

    Mammalian expression

    Patented Mammalian Expression Platform

    A CHO-based platform for complex and glycosylated biologics that require mammalian folding, assembly and post-translational processing.

      Discuss a Mammalian Expression Program

      Capabilities

      From sequence to a documented, transferable process

      Expression, upstream development, recovery, purification, analytical characterization, scale-up and technology transfer, planned around defined program goals.

      01

      Feasibility

      Assess molecule fit and define the target quality profile.

      02

      Expression strategy

      Select the platform route and development mode.

      03

      Upstream development

      Host/cell-line, media, feed and process-mode work.

      04

      Downstream & analytics

      Recovery, purification and characterization.

      05

      Scale-up & transfer

      Documented, transfer-ready process package.

      06

      Manufacture

      Analytical and method development, with 5 L mammalian and 30–1,000 L microbial capacity; 5,000 L planned.

      Explore Capabilities

      Quality & Company

      Quality built into development and supply

      Development and characterization are aligned with ICH guidelines, and every product is manufactured to the requirements of its stated grade, research grade, multi-compendial or GMP.

      Explore Quality & Company

      Discuss your molecule or product requirement

      Tell us what you are developing or sourcing and we will route your enquiry to the right technical and business team.

      Contact SysGene